Outcomes of stage IV patients with colorectal cancer treated in a single institution: What is the key to the long-term survival?

Mukai, Toshiki; Uehara, K.; Aiba, Toshisada; Nakamura, Hayato; Nagino, Masato

doi:10.23922/jarc.2017-021

Cited by 2 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PAMR1 might be considered as an early biomarker of colorectal cancer as in cervical and breast cancers. This finding could help to limit the number of CRC patients diagnosed with aggressive stages (III and IV), correlated with poor prognosis and short overall survival time (Kuo et al, 2003)(Mukai et al, 2018).…”

Section: Resultsmentioning

confidence: 97%

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

Haymour

Chaunavel

Assaf

et al. 2022

Preprint

View full text Add to dashboard Cite

Colorectal cancer (CRC) is becoming one of the most prevalent cancers worldwide. Among cancers, it ranks the third place in terms of incidence and the second in terms of mortality. Even though immunological test allows fast and easy diagnostic method, there is no specific and reliable methods for early detection of CRC. Despite different treatments, high risk of re-occurrence is associated with advanced and metastatic CRC stages. An exhaustive knowledge on specific biomarkers or molecular actors involved in CRC could help to eradicate tumors or limit cancer recurrence. In this study, we focused on PAMR1 (Peptidase Domain Containing Associated with Muscle Regeneration 1), which is already considered as a tumor suppressor in breast and cervical cancers. In silico analysis of RNASeq data showed that PAMR1 was significantly downregulated in CRC tissues compared to their adjacent normal ones, as well as in cervical cancer. Our analysis showed that this downregulation, probably due to promoter hypermethylation, such as in breast cancer tissues, appeared in the four cancer stages as early as the first stage. In consistency with in silico analyses, the expression of PAMR1 was found to be lower at the transcript and protein levels in CRC tissue samples compared to normal ones, as well as in different CRC cell lines (HCT116, HT29, and SW620) compared to normal colon cell line (CCD841CoN). To understand the role of PAMR1 in CRC cancer, recombinant purified PAMR1 or concentrated secretome from CHO overexpressing PAMR1 were used to exogenously treat CRC cell lines with a focus on HT-29 cells as well as Hela cervical cancer cell line known to be sensitive to PAMR1. Transient or stable transfections were also performed to determine the impact of PAMR1 overexpression in HT29 and/or HeLa cells. In this study, we finally showed that presence of PAMR1 could reduce both cell proliferation and cell migration with a positive correlation between these biological effects and PAMR1 quantity. This implies that PAMR1 expresses anti proliferative and anti migrative effects in CRC. Further studies to be done in order to confirm the tumor suppressive role of PAMR1 in CRC.

show abstract

Section: Resultsmentioning

confidence: 97%

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

Haymour

Chaunavel

Assaf

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Many researchers have reported that curative resection might improve long-term survival in patients with stage IV CRC [20-22]. Recent retrospective studies on curatively resected stage IV CRC patients reported a 5-year OS rate of 52.2–57% [22, 23].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Recent retrospective studies on curatively resected stage IV CRC patients reported a 5-year OS rate of 52.2–57% [22, 23]. Moreover, aggressive curative resection with perioperative chemotherapy might improve survival [22]. In general, curative resection and chemotherapy might be the optimal treatment strategy for middle-aged patients with stage IV CRC [9].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer

Hidaka

Maeda

Nakahara

et al. 2018

Gastrointest Tumors

View full text Add to dashboard Cite

Background/Aim: The optimal treatment strategy for elderly patients with stage IV colorectal cancer (CRC) remains controversial due to limited research data. The purpose of this study was to evaluate treatment results and to clarify the prognostic factors, especially poor prognosis factors, in elderly patients with stage IV CRC. Methods: We retrospectively reviewed the data of 82 elderly patients (aged ≥75 years) with stage IV CRC who underwent surgical treatment at our hospital between April 2001 and March 2017. Factors that affected prognosis and the ability to undergo treatment were analyzed via multivariate analysis. Results: The median overall survival (OS) in the patients with high pretreatment serum carbohydrate antigen 19-9 (CA19-9) concentration (> 370 U/mL) was significantly worse than in those with lower serum CA19-9 concentration (0–370 U/mL) (8.5 vs. 19.2 months, p = 0.0059). In univariate analysis, age (≥80 years) (p = 0.014), performance status of 1–3 (p = 0.028), and high pretreatment serum CA19-9 concentration (p = 0.014) were significant prognostic factors for poor OS. By contrast, resection of the primary tumor (p = 0.024), chemotherapy (p < 0.0001), and resection of distant metastasis (p = 0.0005) were significant prognostic factors for favorable OS. Multivariate analysis showed that a high pretreatment serum CA19-9 concentration was an independent prognostic factor for poor OS (p = 0.01). Meanwhile, resection of the primary tumor (p = 0.033), chemotherapy (p < 0.0001), and resection of distant metastasis (p = 0.0008) were prognostic factors for favorable OS. Conclusions: A high pretreatment serum CA19-9 concentration (> 370 U/mL) was a reliable predictive factor for poor prognosis, and aggressive treatments should be performed carefully in these patients. Moreover, various treatments, including surgery and chemotherapy, might improve OS in elderly patients with stage IV CRC.

show abstract

Outcomes of stage IV patients with colorectal cancer treated in a single institution: What is the key to the long-term survival?

Cited by 2 publications

References 28 publications

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer

Contact Info

Product

Resources

About